Archive · 25 Jul 2025
Syngene's Q1 Shows Strong Growth, Plans for Manufacturing Expansion
Syngene, a company that helps other companies with research and manufacturing, had a good start to the year.
Their sales went up by 11%, and their profits jumped up by a lot too.
This growth was thanks to more projects and new clients.
Syngene is also making more products, especially in Bengaluru and Maryland, USA.
Even though things are going well, the company thinks profits might not grow as fast in the future because of the cost of new buildings.
The market for this type of business is big and getting bigger, so Syngene has room to grow.
Syngene International's Q1 revenue grew by 11% due to strong research services.
The company's PAT jumped 61% to ₹87 crore, although growth is expected to moderate.
Pilot project conversions into full-scale programs and direct client engagements fueled the growth.
Syngene is expanding manufacturing capacities, including biologics in Bengaluru and Bayview, Maryland.
The global CDMO market is large and growing, providing significant headroom for Syngene.
- Who
- Syngene International
- What
- Syngene International reported strong Q1 growth driven by research services and manufacturing expansion.
- When
- Q1 FY25
- Where
- Bengaluru, Maryland, and globally.
- Why
- Driven by strong research services, pilot project conversions, and market demand.
Positive Outlook
Cautious Approach
Growth Outlook
Positive Outlook
Strong revenue and PAT growth in Q1, driven by research services and pilot project conversions.
Cautious Approach
Expectation of PAT growth moderation due to depreciation from new facilities.
- Revenue Growth
- 11%
- PAT Growth
- 61%
- PAT
- ₹87 crore
- EBITDA Growth
- 19%
- EBITDA Margin
- 25%
- Market
- Global CDMO
- Market Growth
- 8–9% annually